The efficacy and safety of the short-term combination therapy with ticagrelor and PPIs or H2RA in patients with acute STEMI who underwent emergency PCI

Peng Wei1 | Shujiang Zhuo2 | Qiang Fu3 | Haibo Wang3 | Bin Zong3 | Bangming Cao4 | Liansheng Wang1

1Department of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China
2Department of Cardiology, Hainan Provincial Hospital of Traditional Chinese Medicine, Haikou, China
3Department of Cardiology, The Xuzhou School of Clinical Medicine of Nanjing Medical University, Xuzhou, Jiangsu, China
4Department of Cardiology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China

Abstract
Combination therapy with platelet inhibitors and acid-suppressive agents is recommended for patients with acute ST-segment elevation myocardial infarction (STEMI) who underwent percutaneous coronary intervention (PCI), but there remains a paucity of data to evaluate both the efficacy and safety of these combinations. In this prospective study, a total of 170 patients with acute STEMI who underwent PCI were divided into four groups: pantoprazole + ticagrelor, omeprazole + ticagrelor, ranitidine + ticagrelor, and ticagrelor only. The risk of PCI, antithrombotic efficacy, cardiac function, and main end points were evaluated and compared. No significant differences were found in infarction-related artery perfusion indexes (thrombolysis in myocardial infarction [TIMI], corrected TIMI frame count), the incidence of stent thrombosis after PCI, platelet indicators (platelet count, mean platelet volume, and platelet distribution width), platelet activation (P-selectin and glycoprotein IIb/IIIa levels), platelet aggregation (thrombelastography indicators, such as ADP% and MAADP), myocardial necrosis biomarker (creatine kinase isoenzyme-MB and cardiac troponin I) levels, brain natriuretic peptide levels, the incidence of ischemic end point events, and the incidence of other tissue and organ bleeding events among the four groups. The incidence of gastrointestinal (GI) bleeding events in the proton pump-inhibitor (PPI) group was significantly lower than that in the control group, whereas in the H2 receptor antagonist (H2RA) group it was not significantly different from the control group. The short-term combination therapy with ticagrelor and PPIs or H2RA is safe and effective in patients with acute STEMI after PCI. In addition, the PPIs combined with ticagrelor could reduce the incidence of GI bleeding events without increasing the incidence of ischemic events.
INTRODUCTION

Acute coronary syndrome (ACS) is a clinical syndrome caused by acute myocardial ischemia (MI), including acute ST-segment elevation myocardial infarction (STEMI), acute non-ST-segment elevation myocardial infarction (non-STEMI), and unstable angina. Acute STEMI is the most critical type of ACS due to its rapid onset, dangerous progression, poor prognosis, and high fatality rate.\(^1\) The rupture of the unstable coronary atherosclerotic plaque leading to thrombosis, severe MI, and even necrosis results in the onset of acute STEMI. The key to the successful therapy of acute STEMI is to open the infarction-related artery (IRA) as soon as possible to restore ischemic myocardium and reperfusion. With the development of drug-eluting stents, percutaneous coronary intervention (PCI) has become the first priority for the treatment of acute STEMI.\(^2,3\)

Platelet activation plays a key role in atherosclerotic plaque formation and thrombosis during acute STEMI. To reduce the risk of stent thrombosis and recurrent cardiovascular events after PCI, it is a consensus to use dual antiplatelet therapy (aspirin + ticagrelor or clopidogrel) before and after surgery.\(^4\) But the application of combined antiplatelet therapy also has its disadvantages, which is to increase the incidence of gastrointestinal (GI) complications, such as ulcers and GI bleeding.\(^5,6\) However, abundant evidence showed that the high incidence of bleeding is mainly concentrated within 1 week of the disease course.\(^7\) Hence, it is important to choose the appropriate medications to prevent GI bleeding. It is recommended that patients with myocardial infarction take proton pump inhibitors (PPIs) or H2 receptor antagonists (H2RAs) at the same time as antithrombotic therapy.\(^8\) However, the drug-drug interactions between PPIs and antiplatelet medications (such as omeprazole and clopidogrel) are controversial\(^9,10\) and remain a problem.\(^11,13\) The combination therapy may result in increased inhibition of cytochrome P450 (CYP) enzymes and decreased clopidogrel antiplatelet effect.

Ticagrelor is a P2Y12 reversible inhibitor. It does not require activation and is administered in its active form. Additionally, it does not undergo CYP2C19 metabolism, which is important for PPI co-administration.\(^14\) Ticagrelor exhibits better efficacy than clopidogrel.\(^15\)–\(^17\) Previously, it has been demonstrated that in clopidogrel nonresponders switching to ticagrelor decreased platelet aggregation and improved the platelet resistance.\(^16\) In the PLATO clinical trial, the combinational use of ticagrelor and aspirin showed significantly fewer major end point events.

Study Highlights

WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
The combined antiplatelet therapy for patients with acute ST-segment elevation myocardial infarction (STEMI) who underwent percutaneous coronary intervention (PCI) increases the incidence of gastrointestinal (GI) complications, such as ulcers and GI bleeding. It is recommended that these patients are taking proton pump inhibitors (PPIs) or H2 receptor antagonists (H2RAs) at the same time as antithrombotic therapy. However, there remains a paucity of data to evaluate both the efficacy and safety of these combinations.

WHAT QUESTION DID THIS STUDY ADDRESS?
This study aimed to explore whether there are increased risks of stent thrombosis, other ischemic events, or a decreased antiplatelet effect when ticagrelor is combined with PPIs or H2RAs to prevent GI bleeding to find new economic, effective, and safe treatment.

WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
This study indicates that the application of PPIs or H2RAs in combination with ticagrelor is safe and effective in the treatment of patients with acute STEMI who underwent emergency PCI. The PPIs combined with ticagrelor could reduce the incidence of GI bleeding events without increasing the incidence of ischemic events.

HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
This study provides a clinical trial basis for rational drug use and laying the foundation for finding economical, effective, and safe new treatment of patients with acute STEMI who underwent emergency PCI.

\(^{1,2,3}\) Medicinal Research, China (2019-0509) Yantai Key Research and Development Plan (2019YD065).
or a decreased antiplatelet effect when ticagrelor is combined with PPIs or H2RAs in the treatment of acute STEMI are scarce.

This study aimed to investigate whether there are increased risks of stent thrombosis, other ischemic events, or a decreased antiplatelet effect when ticagrelor is combined with PPIs or H2RAs to prevent GI bleeding.

**METHODS**

**Patients**

This prospective study was approved by the Ethics Committee of the First Affiliated Hospital with Nanjing Medical University, China. A total of 170 patients were hospitalized in our hospital due to acute ST-segment elevation myocardial infarction in September 2016 and received emergency coronary angiography (CAG) and PCI. There were 90 men and 80 women, aged 30–75 years old (mean: 60.51 ± 12.09). Based on the ticagrelor combination with PPIs or H2RAs at the time of treatment, the patients were divided into four groups: group A (PPI group), who received pantoprazole (group A1, 39 cases) or omeprazole (group A2, 43 cases); group B (H2RA group), who received ranitidine (43 cases); and group C, the control group (45 cases used ticagrelor only). All patients signed the informed consent form, and all selected patients were followed up by telephone during hospitalization and within 30 days after discharge.

**Inclusion criteria**

The inclusion criteria were: (1) aged 30–75 years old and indicated for emergency PCI surgery; (2) the STEMI diagnostic criteria comply with the 2010 Acute Myocardial Infarction Diagnostic Criteria of the Chinese Medical Association ([i]) chest pain ≥30 minutes, symptoms cannot be significantly relieved after taking nitroglycerin; [ii] electrocardiogram in at least two limbs leads ST elevation ≥0.1 mV or adjacent pectoral leads ST elevation ≥0.2 mV; [iii] cardiac biomarkers (troponin I) increased, and at least one frequency value exceeded the 99th percentile of the upper limit of the reference value; i.e., the upper limit of normal); (3) the onset time does not exceed 12 h or the onset of more than 12 h still has chest tightness and pain and continuous ST-segment elevation; (4) patients with acute myocardial infarction will not be given revascularization for non-criminal vascular disease (including other parts of the culprit’s blood vessel of myocardial infarction and disease of the non-criminal blood vessel) within 30 days; and (5) the patient and family members agreed to participate in this clinical trial upon admission and signed a written informed consent form before the operation.

**Exclusion criteria**

The exclusion criteria were: (1) patients who have severe adverse reactions to ticagrelor and clopidogrel resistance, are allergic to aspirin, contrast agents, and use glycoprotein (GP) IIb/IIIa receptor antagonists; (2) patients who are not suitable for PCI based on clinical experience or previous examination judgment and CAG diagnosis; (3) patients with acute ST-segment elevation myocardial infarction within 24 h of left main disease, cardiogenic shock, and thrombolysis; (4) patients who have a history of PCI or coronary artery bypass graft surgery; (5) patients with high-risk bleeding or those with active bleeding and surgery or trauma within 3 months before enrollment; (6) patients who have taken PPIs or H2RAs within 1 week; (7) patients with abnormal blood routine (hemoglobin <100 g/L, platelet count <100*10^9/L); (8) patients with previous myocardial infarction or other heart diseases, and those with severe heart failure (New York Heart Association [NYHA] class III–IV); (9) patients with immune system diseases, such as diabetes and other endocrine diseases, digestive ulcers, acute and chronic infections, malignant tumors, hematological diseases, rheumatic connective tissue, etc.; (10) patients with cerebrovascular disease and peripheral vascular disease, etc.; (11) patients with obvious abnormal liver and kidney function (alanine aminotransferase and aspartate aminotransferase caused by non-myocardial infarction increased more than 3 times; blood creatinine level >180 umol/L); (12) patients who have a history of heparin-induced thrombocytopenia; (13) patients with severe uncontrolled hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg); and (14) any other situation that the researcher speculated was not suitable for inclusion in the research.

**Drug administration methods**

**Antiplatelet drug treatment**

Aspirin (Bayaspirin, AG, Germany): a single dose of 300 mg followed by 100 mg once a day. Aspirin is to be taken for life if there is no contraindication.
Ticagrelor (Brilinta; AstraZeneca): a single dose of 180 mg followed by 90 mg twice a day until 12 months after surgery.

Medication in the study group and control group

Study group Patients were immediately given the corresponding PPIs or H2RAs orally on admission followed by routine dosing until discontinuation on day 7.

Group A1 Pantoprazole enteric-coated capsules (Huadong Medicine Co. Ltd.), a single dose of 40 mg followed by 40 mg once a day.

Group A2 Omeprazole enteric-coated capsules (Changzhou Siyao Pharmaceuticals Co. Ltd.), a single dose of 40 mg followed by 20 mg twice a day.

Group B Ranitidine hydrochloride capsules (Hengshan Pharmaceutical Co. Ltd.), a single dose of 300 mg followed by 150 mg twice a day.

Control group Patients were not given the corresponding PPIs or H2RAs.

Other drugs

Patients with indications were simultaneously given low molecular weight heparin, GPIIb/IIIa inhibitors, beta blockers, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, statins, calcium channel blockers, and nitrate esters for treatment.

Coronary intervention diagnosis and treatment (CAG + PCI)

After preprocedural preparations were made, CAG + PCI was carried out in a catheterization room equipped with a fully digital x-ray C-arm angiography machine (Koninklijke Philips N.V.). Transradial or transfemoral approaches were used, although the transradial approach was generally used. Routine disinfection, draping, and local anesthesia with lidocaine were carried out. After the radial artery was palpated and located, a needle was inserted at the site with the most visible pulsation using the Seldinger technique.

After fresh arterial blood was seen, the guidewire was inserted along the needle. The needle was then withdrawn when there was no resistance, and the guidewire was retained. A 6F arterial sheath was inserted along the guidewire. The inner core and steel wire were removed, and 3000 U of heparin sodium was injected into the catheter. For CAG, 6FJL and 6FJR catheters were inserted into the openings of the left and right coronary arteries under the guidance of a J-shaped guidewire.

For imaging, 350 mg/ml of iohexol was used as the contrast agent. At least five projections (left anterior oblique caudal ["spider"], caudal, right anterior oblique caudal, anteroposterior cranial, and right anterior oblique cranial) were performed for the left coronary artery, and at least the left anterior oblique and cranial views were projected for the right coronary artery. Other projections were made when necessary to image the various coronary artery segments fully.

The above procedure was performed by an experienced clinical interventional cardiologist and assessed by two experienced interventional cardiologists. A visual inspection method that is used internationally was used to determine the degree of coronary artery stenosis (i.e., based on the percentage decrease in the diameter of the stenotic site compared with the internal diameter of normal coronary arteries at the distal and proximal ends of the stenotic segment). After a unanimous opinion was achieved and the result was determined, PCI was directly performed on the culprit vessel.

Observation markers

1. Infarction site (anterior wall myocardial infarction and non-anterior wall myocardial infarction).
2. Site of the infarction-related blood vessel (anterior descending branch, circumflex branch, or right coronary artery).
3. Duration from disease onset to balloon angioplasty or stent implantation (i.e., time to achieve coronary artery patency).
4. Pressure at maximum balloon dilatation.
5. Length and diameter of the implanted stent.
6. Thrombolysis in myocardial infarction (TIMI) risk score.
7. Transfemoral or transradial route.
8. Myocardial microcirculatory perfusion markers (TIMI blood flow grade and corrected TIMI frame count [CTFC]).
9. Stent thrombosis.

Collection of blood samples

Five ml of venous blood was immediately collected on admission (before dosing) and 24 h after taking the study
agents, and 5 ml of venous blood was collected on an empty stomach on the morning of day 7 after taking the study agents through the antecubital vein in all patients. During blood sampling, a tourniquet was not tied, and the blood vessel at the puncture site was not slapped. An effort was made to carry out blood sampling in one attempt. After the samples were collected, they were not shaken vigorously to prevent damaging platelets and hemolysis. The samples were processed according to experimental requirements, and relevant test markers were measured.

**Measurement of relevant test markers**

**Three-item platelet test**

The XE-2100D Hematology Analyzer (Sysmex Corp.) was used to measure the platelet count, mean platelet volume, and platelet distribution width immediately on admission, 24 h after taking the study agents, and on day 7 after taking the study agents through hydrodynamic focusing.

**P-selectin (CD62P)**

A human P-selectin enzyme-linked immunosorbent assay (ELISA) kit (CD62P, Shanghai Enzymelink Biotechnology Co., Ltd.) was used to measure CD62P levels according to the manufacturer’s instructions.

**Platelet membrane GP IIb/IIIa**

Double-antibody sandwich ELISA was used to measure GP IIb/IIIa levels in the blood samples according to the manufacturer’s instructions of the human platelet membrane glycoprotein ELISA kit (GP IIb/IIIa, Shanghai Lianshuo Biotechnology Co., Ltd.).

**Thrombelastography**

The TEG 5000 Thrombelastograph Analyzer (Haemoscope Inc.) and a platelet aggregation assay kit (coagulation method) were used according to the manufacturer’s instructions. Five ml of blood was collected from each patient in a citrate tube immediately on admission and 2 h, and then on day 7 after taking the study agents. One ml of blood was added to tubes containing kaolin and was gently mixed (gentle inversion 5 times without vigorous shaking).

Following that, 360 μl of the kaolin-processed blood samples were added to preheated sample cups (20 μl of 0.2 M CaCl₂ was added for the citrate-treated blood samples to restore calcium) before the TEG 5000 Thrombelastograph Analyzer was used to measure the maximum amplitude generated by thrombin (MATHrombin). Ten ml of prepared activator F was added to two cups, and 10 μl of arachidonic acid (AA) and adenosine diphosphate (ADP) were added. To the cups, 360 μl of heparinized whole blood was added.

Then, the blood samples in the two cups were pipetted up and down thrice for mixing and the formation of platelet activator-activated whole blood cross-linked clots. The TEG 5000 Thrombelastograph Analyzer and its software were used to obtain AA%, MAA, ADP%, and MAAADP in order to assess the effects of PPIs or H2RAs on the efficacy of ticagrelor.

**Classical myocardial necrosis markers**

The 7600-020 fully automated biochemical analyzer (Hitachi Ltd.) and creatine kinase isoenzyme-MB (CK-MB) kit (Shanghai Fosun Long March Medical Science Co., Ltd.) were used to detect the level of CK-MB in the four groups of patients at admission, 24 h after taking the study agents, and day 7 after taking the study agents by the immunosuppressive method. The Centaur CP chemiluminescence analyzer (Siemens AG, Germany) and cardiac troponin I (cTnI) kit (SIEMENS) were used to detect the level of cTnI in the four groups of patients at admission, 24 h after taking the study agents, and day 7 after taking the study agents by the chemiluminescence method.

**Brain natriuretic peptide**

Fresh peripheral blood was collected in ethylenediaminetetraacetic acid anticoagulant tubes immediately on admission and 24 h, and then on day 7 after taking the study agents. The Triage fluorescence immunoanalyzer (Biosite Inc.) was used to measure brain natriuretic peptide (BNP) levels according to the instructions.

**IRA perfusion index**

Coronary TIMI blood flow refers to the blood flow of the relevant criminal vessels during heart muscle infarction, which can be divided into 0–III levels, a total of four levels, through coronary angiography based on the following criteria: TIMI level 0: no irrigation (no forward blood flow [contrast agent] filling of the lesions and distant blood vessels); TIMI level I: micro-irrigation (the contrast agent...
can pass through the site of the lesions, but does not pass through the far-end blood vessels); TIMI level II: partial irrigation (the contrast agent can pass through the lesions section, and reach the far end of the lesions of blood vessels, but its filling speed in normal blood vessels is significantly slower); TIMI level III: complete irrigation (the contrast agent can completely and rapidly fill the lesions blood vessels). CTFC is also used as an indicator of the IRA perfusion index. CTFC is calculated as TIMI frame count (TFC) divided by 1.7. The TFC is obtained by counting the number of frames required for coronary arteries to begin to be tinted to a standardized distal marker development during CAG.

**End points**

**Ischemic end point**

The patients in the groups were followed up during hospitalization and within 30 days after discharge. Their primary ischemic end point events (cardiogenic death, non-fatal myocardial infarction or stroke, and requiring emergency coronary revascularization) and secondary ischemia end point events (the single component of primary ischemic end point events) were counted.

**Safety end point (bleeding)**

Regarding TIMI bleeding classification and PLATO test, safety end points include (1) GI bleeding events ([i] occult bleeding: the occult blood test is positive without obvious bleeding; [ii] heavy GI bleeding: obvious hematemesis, heme staining, or significantly decreased hemoglobin [>5 g/dl], significantly decreased hematocrit [greater than 15%]; and [iii] minor bleeding: between hidden bleeding and GI bleeding); (2) bleeding events in other tissues and organs—except for GI bleeding—any bleeding in tissues and organs, including life-threatening and non-life-threatening bleeding.

**Statistical analysis**

SPSS version 22.0 was used for statistical analysis. Measurement data were presented as mean ± SD. One-way analysis of variance test was used for comparison between groups, and SNK-q was used for pairwise comparison between multiple groups. Count data are presented as the number of cases/percent (n/%), and the comparison of multisample rates was analyzed by χ² test or Fisher’s exact probability method.

**RESULTS**

**Comparison of baseline characteristics in each group**

There were no significant differences in gender, age, body mass index, cardiovascular risk factors (smoking history, drinking history, history of hypertension, family history of coronary heart disease, total cholesterol, low-density lipoprotein cholesterol, and triglycerides), medication during the study (whether to use low molecular weight heparin, glycoprotein IIb/IIIa inhibitors, β-receptor blockers, angiotensin-converting enzyme inhibitors [ACEI]/angiotensin receptor blockers [ARBs], statins, calcium channel blockers [CCBs], and nitrate medications), aspartate aminotransferase, alanine aminotransferase, creatinine, blood urea nitrogen, stress blood glucose, and cardiac ejection fraction value of patients in each group (p > 0.05; Table 1).

**Comparison of myocardial infarction-related indicators in each group**

No significant differences were found in the infarct location, infarct-related blood vessel location, coronary artery patency time, maximum balloon inflation pressure, the length and diameter of the implanted stent, and TIMI risk score among each group of patients (p > 0.05; Table 2).

**Comparison of IRA perfusion indexes in each group**

No significant differences were observed in the incidence of TIMI blood flow classification and CTFC among each group of patients (p > 0.05; Figure 1a,b).

**Comparison of incidence of stent thrombosis after PCI in each group**

No cases of confirmed or possible acute stent thrombosis were found. Two cases of confirmed or possible subacute stent thrombosis were found, including one case in group A (1 case in group A1 and 0 case in group A2) and one case in group C. No significant differences in the incidence of acute stent thrombosis or subacute stent thrombosis were found among each group (p > 0.05). There was also no statistically significant difference in the total incidence of stent thrombosis between groups (p > 0.05; Table 3).
Comparison of platelet indicators in each group

No significant differences were found in the platelet indicators (platelet count [PLT], mean platelet volume [MPV], platelet distribution width [PDW]) among the four groups of patients at admission, 24 h after taking the study agents, and day 7 after taking the study agents (p > 0.05; Table 4).

Comparison of P-selectin and GP IIb/IIIa levels in each group

The levels of P-selectin and GP IIb/IIIa of the patients in each group increased at 24 h after taking the study agents, and all showed a downward trend on the seventh day after taking the study agents. No significant differences were found in the P-selectin and GP IIb/IIIa levels among the four groups of patients at admission, 24 h after taking the study agents, and day 7 after taking the study agents (p > 0.05; Figure 1c,d).

Comparison of TEG indicators in each group

No significant differences were found in the platelet inhibition rate (ADP%) and platelet aggregation rate (MA\(_{ADP}\)) of the ADP pathway among each group of patients at admission, 24 h after taking the study agents, and day 7 after taking the study agents (p > 0.05; Figure 1e,f).

---

**TABLE 1** Baseline characteristics of the patients in the study

|                                | Group A1 (N = 39) | Group A2 (N = 43) | Group B (N = 43) | Group C (N = 45) | p value |
|--------------------------------|-------------------|-------------------|-------------------|-------------------|---------|
| Gender (male/female)           | 21/18             | 22/21             | 23/20             | 24/21             | 0.995   |
| Age (year)                     | 61.74 ± 12.12     | 60.40 ± 12.47     | 60.72 ± 11.63     | 59.36 ± 12.44     | 0.844   |
| BMI (kg/m\(^2\))               | 25.90 ± 3.13      | 25.07 ± 2.47      | 25.95 ± 2.64      | 25.67 ± 2.52      | 0.405   |
| Cardiovascular risk factors n (%) |                   |                   |                   |                   |         |
| Smoking                        | 19 (48.7)         | 22 (51.2)         | 20 (46.5)         | 24 (53.3)         | 0.928   |
| Alcoholic                      | 26 (66.7)         | 28 (65.1)         | 28 (65.1)         | 31 (68.9)         | 0.979   |
| Hypertension                   | 15 (38.5)         | 16 (37.2)         | 14 (32.6)         | 18 (40.0)         | 0.902   |
| Family history of CHD          | 4 (10.3)          | 4 (9.3)           | 3 (7.0)           | 5 (11.1)          | 0.922   |
| TC (mmol/L)                    | 4.73 ± 1.04       | 4.76 ± 1.09       | 4.65 ± 1.05       | 4.63 ± 1.09       | 0.930   |
| LDL-C (mmol/L)                 | 3.18 ± 0.67       | 3.21 ± 0.61       | 3.15 ± 0.75       | 3.18 ± 0.78       | 0.978   |
| TG (mmol/L)                    | 1.34 ± 0.49       | 1.32 ± 0.48       | 1.37 ± 0.47       | 1.31 ± 0.46       | 0.939   |
| Medication n (%)               |                   |                   |                   |                   |         |
| Low-molecular-weight heparin   | 39 (100.0%)       | 43 (100.0%)       | 43 (100.0%)       | 45 (100.0%)       | —       |
| Glycoprotein IIb/IIIa inhibitors | 16 (41.0%)       | 16 (37.2%)        | 18 (41.9%)        | 20 (44.4%)        | 0.922   |
| β-receptor blockers            | 20 (51.3%)        | 23 (53.5%)        | 20 (46.5%)        | 28 (62.2%)        | 0.513   |
| ACEI                           | 11 (28.2%)        | 13 (30.2%)        | 13 (30.2%)        | 16 (35.6%)        | 0.897   |
| ARB                            | 1 (2.6%)          | 1 (2.3%)          | 1 (2.3%)          | 2 (4.4%)          | 0.999   |
| Statins                        | 39 (100.0%)       | 43 (100.0%)       | 43 (100.0%)       | 45 (100.0%)       | —       |
| CCB                            | 14 (35.9%)        | 15 (34.9%)        | 14 (32.6%)        | 12 (26.7%)        | 0.798   |
| Nitrate medications            | 23 (59.0%)        | 26 (60.5%)        | 20 (46.5%)        | 27 (60.0%)        | 0.505   |
| Blood test                     |                   |                   |                   |                   |         |
| AST (u/L)                      | 38.03 ± 6.26      | 39.81 ± 7.17      | 40.09 ± 5.89      | 39.58 ± 6.66      | 0.491   |
| ALT (u/L)                      | 35.44 ± 6.42      | 34.95 ± 5.50      | 34.05 ± 5.56      | 34.93 ± 6.07      | 0.751   |
| Creatinine (umol/L)            | 87.09 ± 17.48     | 85.91 ± 13.87     | 88.14 ± 15.22     | 87.54 ± 16.94     | 0.929   |
| BUN (mmol/L)                   | 7.09 ± 2.30       | 7.20 ± 2.21       | 6.51 ± 2.65       | 7.02 ± 2.54       | 0.573   |
| Stress blood glucose (mmol/L)  | 7.39 ± 2.97       | 7.50 ± 2.76       | 7.76 ± 2.61       | 7.50 ± 2.82       | 0.941   |
| EF                             | 0.53 ± 0.07       | 0.49 ± 0.08       | 0.50 ± 0.08       | 0.50 ± 0.07       | 0.264   |

Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ALT, alanine aminotransferase; ARB, angiotensin receptor blockers; AST, aspartate aminotransferase; BMI, body mass index; BUN, blood urea nitrogen; CCB, calcium channel antagonist; CHD, coronary heart disease; EF, ejection fraction; LDL-C, low density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides.
Comparison of myocardial necrosis biomarker (CK-MB and cTnI) and BNP levels in each group

The levels of typical myocardial necrosis markers (CK-MB and cTnI) and BNP levels of patients in each group increased at 24 h after taking the study agents, and all the levels showed a downward trend on the seventh day after taking the study agents. No significant differences were found in CK-MB, cTnI, and BNP levels among groups at admission, 24 h after taking the study agents, and day 7 after taking the study agents (p > 0.05; Figure 1g–i).

Comparison of main end points in each group

No significant differences were found in the incidence of ischemic end point events (including cardiac death, non-fatal myocardial infarction, emergency coronary revascularization, and stroke) among each group of patients (including subgroup A) within 30 days (p > 0.05; Tables 5 and 6). About the safety end point events, the incidence of GI bleeding events in each group of patients was not exactly the same (p < 0.05). The incidence of GI bleeding events in the combination treatment groups (group A and group B) were lower than that in the control group (group C). After pairwise comparison, this incidence of patients in group A was significantly lower than that in group C (p < 0.05; Table 5). There was no significant difference in this incidence of the patients between group A and group B and between group B and group C (p > 0.05), and there was also no significant difference in this incidence of the patients among the subgroups of group A (group A1 and group A2), group B, and group C (p > 0.05; Tables 5 and 6). There was also no significant difference in the incidence of other tissue and organ bleeding events of patients in each group (including subgroup A, p > 0.05; Tables 5 and 6).

DISCUSSION

We indicated that the short-term combination use of ticagrelor and PPIs or H2RAs neither reduced the antiplatelet effect nor increased the occurrence of slow or no-reflow events. Such combination therapy would not generate new damage to cardiac function and affect cardiac function in our observation. Moreover, the combination therapy with ticagrelor and PPIs could reduce the incidence of GI bleeding events without increasing the incidence of ischemic events.

PPIs are benzimidazole derivatives, mainly including omeprazole, lansoprazole, pantoprazole, rabeprazole, etc. It is currently believed that PPIs, in addition to suppressing gastric acid secretion, may also have anti-inflammatory and antioxidant effects in the treatment of acid-related diseases. H2RAs can inhibit the secretion of gastric acid and pepsin by blocking the binding of H2 receptors in gastric mucosal cells that secrete gastric acid to histamine and other substances, thereby reducing the gastric juice volume and hydrogen
FIGURE 1  Comparison of thrombolysis in myocardial infarction (TIMI) blood flow classification (a), corrected TIMI frame count (CTFC) (b), P-selectin level (c), glycoprotein (GP) IIb/IIIa level (d), platelet inhibition rate (ADP%) (e), platelet aggregation rate (MAADP) (f), creatine kinase isoenzyme-MB (CK-MB) level (g), cardiac troponin I (cTnl) level (h), and brain natriuretic peptide (BNP) level (i) in each group.
ion concentration, and antagonizing the vasodilation effect of histamine, protecting the gastric mucosa.\textsuperscript{22} There are currently four generations of such drugs used in clinical practice. The PPIs selected in this study were omeprazole and pantoprazole. The main catalytic enzymes for their liver metabolism are CYP2C19 and/or CYP3A4. The pantoprazole can also be metabolized by the phase II metabolic bypass of sulfotransferase. Drug interactions are not prone to occur. The H2RA chosen in this study was ranitidine, which has small side effects; and only 30% of ranitidine taken is metabolized by the liver. The three drugs are economical, practical, and easy to accept by patients and their families. At the same time, they have their own different liver enzyme competitive inhibition characteristics for the metabolic mechanism of ticagrelor and have good representativeness. In 2019, the US Food and Drug Administration (FDA) recalled ranitidine medicines because some ranitidine medicines might contain low levels of the probable human carcinogen N-nitrosodimethylamine (NDMA).\textsuperscript{23} In April 2020, the FDA requested the complete withdrawal of ranitidine from the market on the grounds that when stored at high temperatures, NDMA levels may increase.\textsuperscript{24} However, there is no long-term epidemiological studies on the risk of cancer caused by long-term exposure to NDMA from specific drugs. Some studies have shown that there was no increase in the risk of various cancers after taking ranitidine. In addition, a few studies that evaluated the cancer risk of ranitidine were flawed.\textsuperscript{24} Therefore, more studies are needed on the safety of ranitidine. These circumstances were not known when we conducted the study in 2016, and the ranitidine was considered safe at that time. Compared with H2RAs, PPIs have high specificity, have a strong and long-lasting effect on inhibiting gastric acid, and can more effectively reduce the risk of GI bleeding caused by antiplatelet therapy.\textsuperscript{25}

TIMI blood flow classification and CTFC are currently commonly used effective methods to evaluate the vascular perfusion of criminal vessels in patients with myocardial

| TABLE 3 | Incidence of stent thrombosis after PCI in each group |
|----------|-----------------------------------------------------|
|          | Group A1 (N = 39) | Group A2 (N = 43) | Group B (N = 43) | Group C (N = 45) | p value |
| Acute stent thrombosis n (%) | | | | | |
| Confirmed | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | — |
| Confirmed or possible | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | — |
| Subacute stent thrombosis n (%) | | | | | |
| Confirmed | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | — |
| Confirmed or possible | 1 (2.6%) | 0 (0.0%) | 0 (0.0%) | 1 (2.2%) | 0.602 |
| Total stent thrombus n (%) | 1 (2.6%) | 0 (0.0%) | 0 (0.0%) | 1 (2.2%) | 0.602 |

Abbreviation: PCI, percutaneous coronary intervention.

| TABLE 4 | Platelets indicators in each group |
|----------|-----------------------------------|
|          | Group A1 (N = 39) | Group A2 (N = 43) | Group B (N = 43) | Group C (N = 45) | p value |
| PLT (*10^9/L) | | | | | |
| At admission | 167.90 ± 35.04 | 166.44 ± 43.18 | 164.42 ± 36.32 | 163.98 ± 38.01 | 0.963 |
| 24 h after taking the study agents | 159.72 ± 39.10 | 157.14 ± 33.44 | 156.93 ± 36.96 | 159.02 ± 38.25 | 0.982 |
| Day 7 after taking the study agents | 204.46 ± 56.04 | 209.60 ± 43.34 | 208.91 ± 52.14 | 212.00 ± 45.25 | 0.918 |
| MPV (fL) | | | | | |
| Hospitalized | 11.64 ± 1.29 | 11.43 ± 1.15 | 11.72 ± 1.32 | 11.65 ± 1.32 | 0.743 |
| 24 h after taking the study agents | 12.61 ± 1.29 | 12.41 ± 1.27 | 12.61 ± 1.63 | 12.59 ± 1.29 | 0.897 |
| Day 7 after taking the study agents | 10.56 ± 1.14 | 10.39 ± 1.03 | 10.53 ± 1.46 | 10.58 ± 1.19 | 0.884 |
| PDW (fL) | | | | | |
| Hospitalized | 15.84 ± 3.44 | 15.53 ± 2.22 | 15.87 ± 2.53 | 16.02 ± 3.08 | 0.879 |
| 24 h after taking the study agents | 16.81 ± 3.83 | 16.26 ± 2.66 | 16.37 ± 2.81 | 16.29 ± 3.20 | 0.853 |
| Day 7 after taking the study agents | 13.72 ± 3.03 | 14.27 ± 2.97 | 13.65 ± 2.73 | 13.57 ± 2.73 | 0.662 |

Abbreviations: MPV, mean platelet volume; PDW, platelet distribution width; PLT, platelet count.
infarction. Compared with the TIMI blood flow classification, CTFC is less affected by the clinical experience of coronary interventional doctors and is more objective and accurate.\textsuperscript{26} In this study, the results showed that no significant differences were found in the TIMI blood flow classification, CTFC, and the incidence of acute stent thrombosis or subacute stent thrombosis and the total incidence of stent thrombosis in each group ($p > 0.05$), suggesting that the PPI or H2RA application was safe.

Platelet activation plays an extremely important role in the development of acute STEMI. The levels of P-selectin and GPIIb/IIIa are indicators of platelet activation and the degree of activation.\textsuperscript{27} In this study, no significant differences were observed in the levels of P-selectin, and GP IIb/
IIIa among the groups at the three time points during the therapy \( (p > 0.05) \). Furthermore, the levels of three routine platelet items (PLT, MPV, and PDW) of patients in each group showed no significant difference at admission, 24 h after taking the study agents, and day 7 after taking the study agents \( (p > 0.05) \). Therefore, the effect of the combination therapy on the number and volume of platelets was eliminated, that is, the interference of platelet number and volume on platelet activation and aggregation was eliminated. These results suggest that the PPIs or H2RAs combined with ticagrelor did not negatively affect the antithrombotic efficacy of ticagrelor. The platelet aggregation can better reflect the clinical efficacy of antiplatelet drugs and the effects of other drugs on the effect of platelets. We have used the more commonly used TEG method for blood dynamic evaluation of platelet aggregation in the whole process. TEG indicators reflect the plasma coagulation dynamics (including the rate of fibrin formation, dissolution, firmness of coagulation, and elasticity). The results in this study suggested there were no significant differences in ADP\% and MA\(_{ADP}\) at admission, 24 h after taking the study agents, and day 7 after taking the study agents \( (p > 0.05) \). Our findings indicated that ticagrelor combined with different PPIs or H2RAs did not affect the platelet aggregation inhibition rate in patients with acute STEMI who underwent PCI, once again proving that the application of PPIs or H2RAs is safe for antithrombotic treatment of ticagrelor.

We also verified the impact of the combination therapy on the myocardial necrosis biomarker (CK-MB and cTnI) and cardiac function (BNP). No significant difference could be found in the levels of CK-MB, cTnI, and BNP among groups, suggesting that the combination therapy neither aggravated MI and hypoxia, nor increased ventricular load and wall tension in patients with acute myocardial infarction. It could be concluded that such combination therapy did not affect the cardiac function.

We analyzed the ischemic end point and safety end point of the combination therapy, referring to the PLATO trial. There was no significant difference in the incidence of ischemic end point events (including cardiac death, non-fatal myocardial infarction, emergency coronary revascularization, and stroke) within 30 days and the incidence of other tissue and organ bleeding events among groups \( (p > 0.05) \). There was no statistically significant difference in the incidence of GI bleeding events between the H2RA group and the control group. In addition the incidence of GI bleeding events in the PPI group was significantly lower than that in the control group \( (p < 0.05) \).

This study has some limitations. It was a single-center research and was limited by the small number of samples collected due to the limitation of the study time. This may lead to insignificant statistical results of ischemic end point events. Further, the short-term 30 days of follow-up was not sufficient to assess the long-term prognosis. The few significant time points (at admission, 24 h after taking the study agents, and day 7 after taking the study agents) were selected due to funding limitations.

**CONCLUSIONS**

The study showed that the short-term application of different PPIs or H2RAs did not reduce the antithrombotic efficacy of ticagrelor and did not increase the occurrence of slow or no-reflow events. The PPIs or H2RAs combined with ticagrelor showed no new damage to the myocardium or cardiac function. The PPIs combined with ticagrelor could reduce the incidence of GI bleeding events without increasing the incidence of ischemic events. These findings indicate that the application of PPIs or H2RAs in combination with ticagrelor is safe and effective in the treatment of patients with acute STEMI who underwent emergency PCI, providing a clinical trial basis for rational drug use and laying the foundation for finding economical, effective, and safe new treatments.

**CONFLICT OF INTEREST**

The authors declared no competing interests for this work.

**AUTHOR CONTRIBUTIONS**
P.W. and S.J.Z. wrote the manuscript. L.S.W., B.M.C., and P.W. designed the research. P.W., Q.F., H.B.W., and B.Z., performed the research. S.J.Z. and B.M.C. analyzed the data. P.W. and L.S.W contributed new reagents/analytical tools.

**ORCID**

Liansheng Wang https://orcid.org/0000-0003-4590-2844

**REFERENCES**

1. Armstrong PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013;368:1379-1387.
2. Pedersen F, Butrymovich V, Kelbaek H, et al. Short- and long-term cause of death in patients treated with primary PCI for STEMI. J Am Coll Cardiol. 2014;64:2101-2108.
3. Gul M, Uslu N, Satilmisoglu H, Ozylmaz SO. When should fQRS be evaluated as a noninvasive prognostic marker in patients undergoing primary PCI with STEMI? Ann Noninvasive Electrocardiol. 2015;20:200-201.
4. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119-177.
5. Abraham NS, Yang EH, Noseworthy PA, et al. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention. *Aliment Pharmacol Ther.* 2020;52:646-654.

6. Gajanana D, Rogers T, Weintraub WS, et al. Ischemic versus bleeding outcomes after percutaneous coronary interventions in patients with high bleeding risk. *Am J Cardiol.* 2020;125:1631-1637.

7. Kwok CS, Sirker A, Farmer A, et al. In-hospital gastrointestinal bleeding following percutaneous coronary intervention. *Catheter Cardiovasc Interv.* 2020;95:109-117.

8. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. *Circulation.* 2008;118:1894-1909.

9. Simon T, Steg PG, Gilard M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. *Circulation.* 2011;123:474-482.

10. Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. *Drug Metab Dispos.* 2004;32:821-827.

11. Chen M, Wei JF, Xu YN, Liu XJ, Huang DJ. A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel. *Cardiovasc Ther.* 2012;30:e227-e233.

12. Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. *Am Heart J.* 2009;157:148.e1–148.e5.

13. Gilard M, Arnaud B, Cornily J-C, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. *J Am Coll Cardiol.* 2008;51:256-260.

14. Dobesh FP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. *Pharmacotherapy.* 2014;34:1077-1090.

15. Molina-Cuadrado E, Mateo-Carrasco H, Nieto-Guindo P, Rodríguez-Gómez P. Long-term cost-effectiveness of ticagrelor versus clopidogrel in acute coronary syndrome in Spain. *Farm Hosp.* 2014;38:266-275.

16. Gurbel PA, Bilden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. *Circulation.* 2009;120:2577-2585.

17. Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. *Circulation.* 2010;122:2131-2141.

18. Rao SV, O’Grady K, Pieper KS, et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. *J Am Coll Cardiol.* 2006;47:809-816.

19. James S, Åkerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. *Am Heart J.* 2009;157:599-605.

20. Edwards SJ, Lind T, Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs. *Aliment Pharmacol Ther.* 2006;24:743-750.

21. Ahrens D, Chenot JF, Behrens G, Grimmsmann T, Kochen MM. Appropriateness of treatment recommendations for PPI in hospital discharge letters. *Eur J Clin Pharmacol.* 2010;66:1265-1271.

22. Tolbert MK. Gastroprotective therapy. *Vet Clin North Am Small Anim Pract.* 2021;51:33-41.

23. Mahase E. FDA recalls ranitidine medicines over potential cancer causing impurity. *BMJ.* 2019;367:l3832.

24. Wagner JA, Dinh JC, Lightdale JR, Gold BD, Colombo JM. Is this the end for ranitidine? NDMA presence continues to confound. *Clin Transl Sci.* 2021;14:1197-1200.

25. Yamane K, Kato Y, Tazaki J, et al. Effects of PPIs and an H2 blocker on the antiplatelet function of clopidogrel in Japanese patients under dual antiplatelet therapy. *J Atheroscler Thromb.* 2012;19:559-569.

26. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. *Circulation.* 2002;105:1909-1913.

27. von Hundelshausen P, Schmitt MM. Platelets and their chemokines in atherosclerosis-clinical applications. *Front Physiol.* 2014;5:294.

28. Cotton JM, Worrall AM, Hobson AR, et al. Individualised assessment of response to clopidogrel in patients presenting with acute coronary syndromes: a role for short thrombelastography? *Cardiovasc Ther.* 2010;28:139-146.

---

**How to cite this article:** Wei P, Zhuo S, Fu Q, et al. The efficacy and safety of the short-term combination therapy with ticagrelor and PPIs or H2RA in patients with acute STEMI who underwent emergency PCI. *Clin Transl Sci.* 2022;15:477–489. doi:10.1111/cts.13165.